Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:6760710.
doi: 10.1155/2016/6760710. Epub 2015 Dec 28.

Type 2 Diabetes and ADP Receptor Blocker Therapy

Matej Samoš  1 , Marián Fedor  2 , František Kovář  1 , Michal Mokáň  1 , Tomáš Bolek  1 , Peter Galajda  1 , Peter Kubisz  2 , Marián Mokáň  1
Affiliations
Review

Type 2 Diabetes and ADP Receptor Blocker Therapy

Matej Samoš et al. J Diabetes Res. 2016.

Abstract

Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patients with T2D show significantly higher residual platelet reactivity on ADP receptor blocker therapy and are more frequently represented in the group of patients with HTPR. This paper reviews the current knowledge about possible interactions between T2D and ADP receptor blocker therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
LTA with specific inducers (arachidonic acid: black curve, adenosine diphosphate: blue curve) showing difference between HTPR (a) and sufficient antiplatelet response (b) in T2D patient with acute ST-elevation myocardial infarction.
See this image and copyright information in PMC

References

    1. Aronson D., Bloomgarden Z., Rayfield E. J. Potential mechanisms promoting restenosis in diabetic patients. Journal of the American College of Cardiology. 1996;27(3):528–535. doi: 10.1016/0735-1097(95)00496-3. - DOI - PubMed
    1. Tschoepe D., Roesen P., Kaufmann L., et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. European Journal of Clinical Investigation. 1990;20(2):166–170. doi: 10.1111/j.1365-2362.1990.tb02264.x. - DOI - PubMed
    1. Kubisz P., Chudý P., Staško J., et al. Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus. Acta Diabetologica. 2010;47(2):119–124. doi: 10.1007/s00592-009-0127-2. - DOI - PubMed
    1. Chudý P., Kotuličová D., Staško J., Kubisz P. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Blood Coagulation & Fibrinolysis. 2011;22(6):493–498. doi: 10.1097/mbc.0b013e328346f8ca. - DOI - PubMed
    1. Amsterdam E. A., Wenger N. K., Brindis R. G., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–2394. doi: 10.1161/cir.0000000000000133. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources